Toxicity information regarding cilgavimab is not readily available. Patients experiencing an overdose are at an increased risk of severe adverse effects. Symptomatic and supportive measures are recommended.L39411
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of blocking this interaction reduce viral load and improve clinical symptoms of infection.A243356, A243361 Cilgavimab (formerly AZD1061) is a recombinant monoclonal antibody produced in Chinese hamster ovary (CHO) cells derived from a neutralizing antibody isolated from a patient with a natural history of SARS-CoV-2 infection and modified through targeted amino acid substitutions to exhibit an extended (~85-day) half-life.A243351, A243356, L39411 As the RBD binding site of cilgavimab does not overlap with that of tixagevimab, the two can be administered to synergistically impair SARS-CoV-2 infection in individuals who may be exposed to the virus.A243351, A243361, L39411
Cilgavimab is not approved for any indication by the FDA. Cilgavimab, in combination with tixagevimab, was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for whom vaccination is not recommended. The combination is co-packaged and available under the name EVUSHELD (formerly AZD7442).L39411 EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,L41454 and was approved in Canada soon after, on April 14, 2022.L41549
In October 2022, the FDA and Health Canada released safety alerts regarding the risk of developing COVID-19 when exposed to SARS-CoV-2 variants not neutralized by EVUSHELD. Certain SARS-CoV-2 Omicron subvariants may be associated with resistance to monoclonal antibodies, such as EVUSHELD. The FDA and Health Canada advise healthcare providers to inform patients of this risk.L43772,L43777
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Cilgavimab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Cilgavimab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Cilgavimab. |
| Estrone | Estrone may increase the thrombogenic activities of Cilgavimab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Cilgavimab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Cilgavimab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Cilgavimab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Cilgavimab. |
| Estriol | Estriol may increase the thrombogenic activities of Cilgavimab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Cilgavimab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Cilgavimab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Cilgavimab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Cilgavimab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Cilgavimab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Cilgavimab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Cilgavimab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Cilgavimab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Cilgavimab. |
| Equol | Equol may increase the thrombogenic activities of Cilgavimab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Cilgavimab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Cilgavimab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Cilgavimab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Cilgavimab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Cilgavimab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Cilgavimab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Cilgavimab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Cilgavimab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Cilgavimab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Cilgavimab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Cilgavimab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Cilgavimab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Cilgavimab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Cilgavimab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Cilgavimab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Cilgavimab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cilgavimab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Cilgavimab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Cilgavimab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Cilgavimab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Cilgavimab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Cilgavimab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Cilgavimab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Cilgavimab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cilgavimab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Cilgavimab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cilgavimab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Cilgavimab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Cilgavimab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cilgavimab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Cilgavimab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Cilgavimab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Cilgavimab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Cilgavimab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Cilgavimab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Cilgavimab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Cilgavimab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Cilgavimab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Cilgavimab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Cilgavimab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Cilgavimab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Cilgavimab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Cilgavimab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Cilgavimab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Cilgavimab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Cilgavimab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Cilgavimab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Cilgavimab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Cilgavimab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Cilgavimab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Cilgavimab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Cilgavimab. |
| Hepatitis B immune globulin | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Cilgavimab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Cilgavimab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Cilgavimab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Cilgavimab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Cilgavimab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Cilgavimab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Cilgavimab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Cilgavimab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Cilgavimab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Cilgavimab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Cilgavimab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Cilgavimab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Cilgavimab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Cilgavimab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Cilgavimab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Cilgavimab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Cilgavimab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Cilgavimab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Cilgavimab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Cilgavimab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Cilgavimab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Cilgavimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Cilgavimab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Cilgavimab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Cilgavimab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Cilgavimab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Cilgavimab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Cilgavimab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Cilgavimab. |